Authors
Latest:
Considerations for the Management of Oncology Patients During the COVID-19 PandemicABSTRACT Worldwide incidence and mortality due to the coronavirus disease 2019 (COVID-19) pandemic is greatest in the United States, with the initial epicenter in New York. In Nassau County, New York, where we practice, our institution has had more than 2500 cases and has discharged from the hospital more than 1000 patients. As many academic and private institutions have swiftly shifted their clinical and research priorities to address the pandemic, data are emerging regarding both the impact of malignancy on COVID-19 outcomes as well as the challenges faced in assuring that cancer care remains unimpeded. Of concern, recent studies of cancer patients primarily in China and Italy have suggested that advanced malignancy is associated with increased susceptibility to severe COVID-19 infection. At present, more than 500 clinical trials are underway investigating the pathogenesis and treatment of COVID-19, including expanded use of oncology drugs, such as small molecular inhibitors of cytokine pathways. Here, we begin by reviewing the latest understanding of COVID-19 pathophysiology and then focus our attention on the impact of this virus on hematologic and oncologic practice. Finally, we highlight ongoing investigational treatment approaches that are so relevant to the care of oncology patients during this extraordinary pandemic.
Latest:
Enfortumab Vedotin Combo Data in Urothelial Carcinoma Are ‘Compelling’Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
Latest:
Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic ReviewDanazol was reviewed as an effective treatment option for patients with myelodyspplastic syndromes, according to a recently published article by Sangam Shah, MBBS, et al.
Latest:
Acalabrutinib/Chemotherapy Poised to Be Effective in High-Risk MCLAcalabrutinib improves efficacy in high-risk patients like those with TP53 mutations, those with complex cytogenetics, and those with high proliferative rates in MCL.
Latest:
Key Takeaways and Clinical Pearls from SKIPPirrPanelists discuss key takeaways from the analysis and offer clinical pearls on incorporating prophylactic dexamethasone 8 mg into treatment with amivantamab and lazertinib for community colleagues.
Latest:
Traversing the Complexities of Non-Clear Cell Renal Cell CarcinomaA brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.
Latest:
Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOLAuthors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.
Latest:
Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid LeukemiaInvestigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Expanding Horizons in T-Cell Lymphoma Therapy: Focus on Personalized Treatment StrategiesSeveral lymphoma experts discuss the current T-cell lymphoma landscape, the need for new therapies, and ongoing research in the space.
Latest:
HER2+ Breast Cancer Clinical PearlsAdvice for community physicians treating HER2+ breast cancer.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Enfortumab Vedotin PFS May Improve Despite Specific AEs in Bladder CancerPatients with neuropathy experienced a longer PFS with enfortumab vedotin vs those without neuropathy, skin rash, or hyperglycemia.
Latest:
Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature ReviewInvestigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.
Latest:
Multidisciplinary Efforts are 'Essential' to Manage Gynecologic Cancer SymptomsA recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.
Latest:
Treatment of Multiple Myeloma: Q&A Session With Yale Cancer Center and SatellitesA Q&A session with the expert panel.
Latest:
Decisional Capacity Determination in Patients With CancerExperts discuss the process of assessing decision-making capacity in patients with cancer.
